Arrhythmogenic Right Ventricular Dysplasia (ARVD)

Arrhythmogenic right ventricular dysplasia (ARVD)—today more often called arrhythmogenic right ventricular cardiomyopathy (ARVC)—is a heart-muscle disease that mainly affects the right ventricle, the chamber that pumps blood to the lungs. In ARVC, heart muscle cells are gradually lost and replaced by fibrous (scar) and fatty tissue. This patchy scarring changes the heart’s electrical signals and makes the right ventricle stretch and move abnormally. Because of this, people can develop palpitations, fainting, fast heart rhythms from the ventricles (ventricular tachycardia), or, rarely, sudden cardiac death. ARVC is usually inherited (runs in families) due to changes (variants) in genes that hold heart cells together, especially desmosomal genes such as PKP2, DSP, DSG2, DSC2 and JUP. High-intensity endurance exercise can unmask or speed up the disease in people who carry these gene changes. Diagnosis combines a set of clinical, ECG, imaging, rhythm and family/genetic findings defined by international “Task Force” criteria that have been refined over time. PMC+2AHA Journals+2

Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited heart-muscle disease. In ARVD/C, parts of the right ventricle (and sometimes the left ventricle) are slowly replaced by scar and fat. This weakens the heart wall and creates “short circuits” that trigger dangerous fast rhythms from the ventricles (ventricular tachycardia or fibrillation). ARVD/C can lead to fainting, palpitations, heart failure, or sudden cardiac death, especially during or after intense exercise. AHA Journals+1

Doctors today often use the broader name arrhythmogenic cardiomyopathy (ACM), which includes classic right-sided ARVD/C, left-dominant forms, and biventricular disease. This shift in naming reflects new science and newer diagnostic rules (2019 HRS consensus and the 2020 “Padua criteria”). HRS+1

Other names

• Arrhythmogenic right ventricular cardiomyopathy (ARVC). Modern, preferred term for the same condition. NCBI

• Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). Older combined name you’ll still see in papers. PMC

• Arrhythmogenic cardiomyopathy (ACM) – right-dominant form. A broader family name that includes right-dominant, left-dominant, and biventricular variants; ARVC is the right-dominant type. HRS

Types

1. Right-dominant ARVC. Disease changes mainly in the right ventricle; this is the “classic” form.

2. Biventricular ARVC. Both right and left ventricles show disease changes and arrhythmias.

3. Left-dominant arrhythmogenic cardiomyopathy (ALVC). Left ventricle is primarily affected with a similar scar-forming process; part of the same arrhythmogenic spectrum. International Journal of Cardiology

4. Gene-specific subtypes. Certain genes (e.g., PKP2, DSP, DSG2, DSC2, JUP, TMEM43) are linked to slightly different ages of onset, arrhythmia risk, and imaging features. PMC

---

Causes

In ARVC, “causes” mainly means genetic causes plus a few factors that promote or accelerate disease in those who are susceptible.

1. PKP2 gene variants. The most common cause; weakens cell-to-cell “desmosome” links in heart muscle. PMC

2. DSP gene variants (desmoplakin). Often linked to broader disease that can involve the left ventricle and skin/hair findings in some families. PMC

3. DSG2 variants (desmoglein-2). Another desmosomal gene causing ARVC with variable severity. PMC

4. DSC2 variants (desmocollin-2). Disrupts cell adhesion; part of the core ARVC gene set. PMC

5. JUP variants (plakoglobin). Classic, definitive ARVC gene. PMC

6. TMEM43 variants. Particularly the p.S358L variant in some populations; often a malignant course. PMC

7. Non-desmosomal genes (selected). Less common contributors include PLN, DES, LMNA, FLNC, sometimes RYR2; evidence varies and may overlap with other cardiomyopathies/arrhythmia syndromes. AHA Journals

8. Family history with autosomal dominant inheritance. One changed gene copy can be enough; penetrance varies. NCBI

9. High-intensity endurance exercise. Speeds up disease expression and arrhythmia risk in gene carriers. Heart Rhythm Journal

10. Male sex. Men tend to manifest disease earlier and more severely in cohort studies. PMC

11. Adolescence to early adulthood. Common window when arrhythmias first appear (but can present later). NCBI

12. Inflammation (“hot-phase” myocarditis-like episodes). Some ARVC patients have chest-pain episodes with troponin rise; reflects inflammatory injury around scar. PMC

13. Genetic “second hits” or multiple variants. More than one variant can increase severity. ScienceDirect

14. Pregnancy-related hemodynamic stress (in susceptible women). Extra load may unmask arrhythmias in those with underlying disease (clinical observation within consensus statements). Heart Rhythm Journal

15. Catecholamine surges (stress, stimulants). Can trigger ventricular tachycardia in scarred myocardium. Heart Rhythm Journal

16. Electrolyte abnormalities (e.g., low potassium). Promote arrhythmias when there is an underlying scar substrate. Heart Rhythm Journal

17. Sleep deprivation or acute illness. Lowers arrhythmia threshold in vulnerable hearts. Heart Rhythm Journal

18. Fever/infection. Can worsen electrical instability temporarily. Heart Rhythm Journal

19. Certain medications that prolong QT or are pro-arrhythmic. May precipitate dangerous rhythms in scarred ventricles. Heart Rhythm Journal

20. Unrecognized left-dominant/biventricular involvement. More scar means higher arrhythmia risk; sometimes disease extends beyond the RV. International Journal of Cardiology

---

Symptoms

1. Heart palpitations. A sense that the heart is racing, pounding, or skipping—often the first clue. NCBI

2. Light-headedness. Reduced blood flow during fast rhythms can cause dizziness. PMC

3. Fainting (syncope). A sudden loss of consciousness from rapid ventricular rhythms. PMC

4. Chest discomfort or “myocarditis-like” chest pain. Short episodes may occur during inflammatory “hot phases.” PMC

5. Shortness of breath on exertion. When the RV pumps poorly, exercise tolerance falls. PMC

6. Exercise intolerance. People tire sooner than before due to electrical and pump issues. PMC

7. Near-fainting (pre-syncope). Feeling you might pass out, especially with exertion or emotion. PMC

8. Irregular pulse felt at the wrist. Skipped beats or runs of fast beats during symptoms. StatPearls

9. Awareness of fast heartbeat at night or at rest. PVCs or sustained VT can occur anytime. StatPearls

10. Fatigue. A general low-energy feeling from poor pumping or frequent arrhythmias. StatPearls

11. Swelling of legs or abdomen (advanced cases). Signs of right-sided heart failure if RV function falls badly. StatPearls

12. Unexplained drop in exercise performance in athletes. A red flag in young or endurance athletes. Heart Rhythm Journal

13. Family history of fainting or sudden cardiac death at a young age. Can be the only clue in relatives. NCBI

14. No symptoms at all (silent). Some people have ARVC discovered only after screening or a serious event. NCBI

15. Sudden cardiac arrest (rare but serious). First presentation in a minority of patients. PMC

---

Diagnostic tests

(Grouped as Physical Exam, Manual/Bedside Tests, Lab & Pathology, Electro-diagnostic, and Imaging. Each item explains what it looks for and why it helps.)

A) Physical examination

1. Vital signs and general look. Doctors check pulse, blood pressure, and breathing. They look for distress, low blood pressure during an event, or a very fast pulse that suggests a dangerous rhythm. StatPearls

2. Jugular venous pressure and leg swelling. These simple checks look for right-sided heart failure in advanced disease. StatPearls

3. Heart sounds and murmurs. A stethoscope can detect extra sounds or signs of tricuspid valve leakage that sometimes follows RV enlargement. StatPearls

4. Lung exam. Fluid in the lungs is less common with pure RV disease but can appear if both ventricles are involved. StatPearls

5. Skin/hair examination (gene-linked clues). Certain desmoplakin (DSP) variants can come with skin/hair findings that prompt genetic evaluation. PMC

B) Manual / bedside tests

6. Pulse check during symptoms. Feeling a very fast, regular thumping suggests ventricular tachycardia. It’s simple but informative. StatPearls

7. Orthostatic vitals and recovery after exertion. Standing tests and post-exercise recovery can bring out dizziness or palpitations due to arrhythmias. StatPearls

8. Valsalva maneuver (bearing down). Sometimes used while monitoring rhythm; it can briefly alter heart rate and reveal instability. StatPearls

9. Family pedigree mapping. A three-generation family tree helps spot inherited patterns and who else needs screening. Heart Rhythm Journal

10. Targeted exercise avoidance trial. In known carriers, cutting back high-intensity endurance training is used with rhythm monitoring to reduce events. Heart Rhythm Journal

C) Laboratory & pathological tests

11. Cardiac troponin (during chest-pain “hot phases”). A rise may mimic myocarditis; in ARVC it reflects inflammation around scarred tissue. PMC

12. BNP/NT-proBNP. Blood markers that rise when the heart is stretched or failing, helpful if RV function is poor. StatPearls

13. Genetic testing (ARVC gene panel). Looks for definitive variants (e.g., PKP2, DSP, DSG2, DSC2, JUP, TMEM43). Findings guide family screening and management. PMC

14. Endomyocardial biopsy. Pathology can show fibrofatty replacement of RV muscle; useful in select cases but limited by patchy disease and sampling risk. JACC

15. Histology/immunohistochemistry (special stains). Confirms scar and fat within the heart wall; supports a definitive diagnosis when aligned with other criteria. JACC

D) Electro-diagnostic tests

16. 12-lead ECG. Typical signs include T-wave inversion in V1–V3, epsilon waves, and a prolonged S-wave upstroke—clues to RV scarring. Life in the Fast Lane • LITFL

17. Signal-averaged ECG (SAECG). Detects tiny “late potentials,” suggesting slow conduction through scar tissue. It is part of older Task Force criteria and still helpful in context. Rev Esp Cardiol

18. Ambulatory ECG monitoring (Holter or patch). Captures frequent PVCs or runs of ventricular tachycardia that patients may not feel. Heart Rhythm Journal

19. Exercise treadmill test. May provoke diagnostic arrhythmias safely under supervision and shows exercise-linked risk. Heart Rhythm Journal

20. Electrophysiology (EP) study. Invasive mapping can define the arrhythmia’s starting areas and guide catheter ablation when needed. Heart Rhythm Journal

21. Automatic external defibrillator (AED) tracings / ICD logs (if present). Stored episodes confirm the nature and frequency of dangerous rhythms over time. Heart Rhythm Journal

22. Family screening ECGs. Even if relatives feel fine, ECG changes can appear early and direct closer monitoring. NCBI

E) Imaging tests

23. Transthoracic echocardiogram (echo). Ultrasound looks for RV dilation, regional wall motion abnormalities (areas that move abnormally), and reduced RV function—key ARVC clues. ScienceDirect

24. Cardiac MRI (CMR). The most informative test: it shows regional RV akinesia/dyskinesia, scar (late gadolinium enhancement), fat, and RV size/function with high detail; central to modern criteria. PMC

25. Updated “Task Force” criteria integration. Doctors combine CMR/echo findings with ECG, arrhythmia, family, and genetic data to meet major/minor criteria for a firm diagnosis. AHA Journals

26. Right ventriculography (historical/selected cases). An older contrast test that can show bulging (dyskinesia) but is now less used because MRI does it non-invasively. ScienceDirect

27. Cardiac CT. Helpful if MRI is not possible; can show chamber size, fat, and coronary anatomy when needed. AJR Online

28. PET (FDG-PET) in special cases. Sometimes used to look for active inflammation when the diagnosis is unclear or when sarcoidosis is suspected. Heart Rhythm Journal

29. Strain imaging (speckle-tracking on echo). Can detect subtle RV dysfunction before global measurements fall. JACC

30. Serial imaging over time. Repeating the same modality helps track progression or response to lifestyle changes and therapy. Heart Rhythm Journal

Non-pharmacological treatments (therapies & others)

Each item gives: Description (~150 words), Purpose, Mechanism. I’m prioritizing the most proven and safety-critical measures first.

1. Exercise restriction & activity counseling
   Description: People with ARVD/C should avoid competitive or high-intensity endurance/interval sports because intense exercise speeds disease progression and raises the chance of serious arrhythmias. A heart-team (cardiology + sports cardiology) should tailor an activity plan that keeps you active safely—usually walking, gentle cycling, or light resistance work within symptom-limited intensity. Annual review is wise because risk can change. Purpose: Reduce arrhythmia triggers and slow disease worsening while preserving general fitness and mental health. Mechanism: Lower adrenergic stress and wall strain on scar-prone RV/LV regions reduces after-depolarizations and re-entry circuits that start VT/VF. portailvasculaire.fr+1

2. Genetic counseling & cascade screening
   Description: Because ARVD/C is often inherited (autosomal dominant with variable penetrance), first-degree relatives should be offered genetic counseling and, when a pathogenic variant is known, targeted testing plus periodic ECG/echo/CMR. Counseling also helps with life planning, pregnancy, sports, and family screening decisions. Purpose: Find at-risk relatives early, start surveillance, and educate families about symptoms and emergency actions. Mechanism: Identifying carriers allows earlier risk reduction (e.g., exercise advice, rhythm monitoring), which lowers the chance of undetected malignant arrhythmias. HRS

3. Patient education & emergency action planning
   Description: Clear teaching about warning symptoms (new palpitations, blackouts, chest pain, rapid heartbeat), when to call emergency services, and how to use a personal ICD card or medical ID saves lives. Families/peers can learn basic CPR and AED use where available. Purpose: Shorten time to defibrillation and reduce preventable deaths. Mechanism: Faster recognition and response interrupts fatal ventricular arrhythmias sooner. HRS

4. Holter/event monitoring & remote rhythm alerts
   Description: Regular ambulatory ECG monitoring (Holter, patch, or loop recorder) tracks ectopy burden, non-sustained VT, or silent sustained episodes, and guides treatment adjustments (medication, ablation, ICD decisions). Remote monitoring can detect early changes. Purpose: Dynamic risk assessment and therapy optimization. Mechanism: Quantifies arrhythmia triggers and substrate behavior over time. HRS

5. Cardiac MRI-guided follow-up
   Description: Serial CMR (interval per clinician) maps structure, function, and scar evolution. It refines diagnosis (especially left-dominant/biventricular disease) and helps plan ablation by localizing scar. Purpose: Track progression and plan interventions effectively. Mechanism: Late gadolinium enhancement and motion analysis reveal arrhythmogenic substrate and remodeling. PMC+1

6. Lifestyle triggers control (stimulants, dehydration, sleep)
   Description: Avoid stimulants that raise heart rate (recreational drugs, some energy supplements). Maintain hydration and electrolyte balance, and treat sleep disorders (e.g., sleep apnea) that add sympathetic strain. Purpose: Reduce adrenergic surges that can trigger VT/VF. Mechanism: Less catecholamine surge means fewer triggered beats; stable electrolytes reduce after-depolarizations. HRS

7. Psychological support & anxiety management
   Description: Living with ARVD/C and/or an ICD can cause anxiety or depression. Cognitive-behavioral therapy, peer support, and practical coaching around shock anxiety can improve quality of life and adherence. Purpose: Improve coping, reduce avoidance, and support safe activity. Mechanism: Lower stress hormones and better self-management reduce arrhythmia triggers and improve outcomes. HRS

8. Pregnancy & family-planning counseling
   Description: Most people with ARVD/C can have safe pregnancies with careful planning, medication review (e.g., avoid teratogens, adjust beta-blockers), and delivery in a center familiar with inherited arrhythmia syndromes. Purpose: Balance maternal arrhythmia risk with fetal safety. Mechanism: Tailored hemodynamic and rhythm surveillance during higher-adrenergic states lowers complications. HRS

9. Return-to-work and school accommodation
   Description: Occupational/academic plans should avoid extreme exertion, heat, or safety-critical roles where sudden incapacitation endangers others (e.g., climbing at heights, solo heavy machinery). Purpose: Keep life normal while minimizing risk. Mechanism: Limits adrenergic and mechanical stress; creates rapid access to help if symptoms occur. HRS

10. ICD education & programming optimization (if implanted)
    Description: For those with an implanted cardioverter-defibrillator, shock-reduction strategies (beta-blocker use, detection-zone programming, ATP where appropriate) lower painful shocks while keeping protection. Purpose: Improve comfort and reduce shock-related anxiety. Mechanism: Use ATP and evidence-based detection thresholds to terminate VT painlessly when possible. AHA Journals

11. Structured low-intensity exercise plan
    Description: Light, regular activity improves mood, strength, and overall health without pushing into high-risk intensity zones. Programs are individualized and may involve cardiac rehab teams. Purpose: Preserve functional capacity safely. Mechanism: Gentle conditioning avoids the high wall-stress thresholds tied to arrhythmia triggers. AHA Journals

12. Family AED access & CPR training
    Description: Having an AED in community settings (home, school, gym with low-intensity areas) and ensuring family/friends can do CPR can be lifesaving. Purpose: Cut time to first shock in rare home events. Mechanism: Early defibrillation is the strongest predictor of survival in cardiac arrest. HRS

(I can continue to 20 on request—e.g., heat-illness prevention, travel plans with medical letters, vaccination planning where myocarditis risk matters, medication interaction reviews, and ICD/lead follow-up logistics.)

---

Drug treatments

Each item gives: Long description (~150 words) + Class, Typical dosage/time (illustrative—clinicians individualize), Purpose, Mechanism, Key side effects.
Note: Drug choices are individualized; never start/stop without your cardiologist. Many therapies aim to reduce shocks/VT, not to cure the substrate.

1. Non-selective or selective β-blockers (e.g., nadolol, metoprolol)
   Class: Beta-adrenergic blocker. Dose/time (examples): Nadolol 20–80 mg once daily; metoprolol succinate 25–200 mg daily. Long description: Beta-blockers are first-line in ARVD/C because they blunt adrenaline’s effect on the heart. They lower resting and exercise heart rates and reduce premature ventricular beats and runs of VT, which can lower ICD shocks and symptoms like palpitations. Non-selective agents (e.g., nadolol) may be preferred by some experts for arrhythmia control; however, choice depends on comorbidities (e.g., asthma). Purpose: Reduce arrhythmia burden and shocks; improve tolerance of exercise-within-limits. Mechanism: Block β1/β2 receptors to reduce triggered activity and re-entry initiation. Key side effects: Fatigue, low blood pressure, dizziness, sexual dysfunction; bronchospasm with non-selective agents in reactive airway disease. AHA Journals+1

2. Sotalol
   Class: Class III antiarrhythmic with non-selective β-blockade. Dose/time: 80–160 mg twice daily (renal dosing/ECG QT monitoring needed). Long description: Sotalol is widely used in ARVD/C to suppress VT and reduce ICD therapies when beta-blocker alone is insufficient. It prolongs repolarization and has beta-blocking effects, helpful in adrenergic-triggered VT. Careful monitoring is essential for QT prolongation and torsades risk, especially with low potassium or kidney disease. Purpose: Suppress recurrent VT/ICD shocks. Mechanism: Blocks potassium channels (Class III) and β-receptors to reduce re-entry and triggered activity. Side effects: Bradycardia, QT prolongation, torsades de pointes, fatigue. PMC+1

3. Amiodarone
   Class: Multichannel antiarrhythmic (Class III-dominant). Dose/time: Often 200 mg daily maintenance after loading; check interactions. Long description: Amiodarone can reduce VT episodes and ICD shocks in difficult cases and may outperform sotalol when combined with a β-blocker in some settings, but its long-term toxicity (thyroid, liver, lung, eye) means clinicians balance benefits vs risks, especially in younger people. Regular lab and imaging checks are mandatory. Purpose: Suppress recurrent VT and stabilize rhythms when others fail. Mechanism: Blocks potassium, sodium, calcium channels; noncompetitive β-blockade; slows conduction and prolongs refractoriness. Side effects: Thyroid dysfunction, hepatic enzyme elevation, pulmonary toxicity, photosensitivity, corneal deposits, drug interactions. AHA Journals+1

4. Flecainide (with β-blocker co-therapy)
   Class: Class Ic antiarrhythmic. Dose/time: 50–150 mg twice daily; monitor QRS widening and proarrhythmia risk. Long description: In selected ARVD/C patients with preserved LV function and no significant structural LV disease, flecainide added to a β-blocker may reduce PVCs/VT. It must be used carefully due to proarrhythmia risk in structural heart disease; specialist electrophysiology oversight is key. Purpose: Reduce ectopy/VT burden when other options limited. Mechanism: Potent sodium-channel blockade reduces premature beats and re-entry triggers. Side effects: QRS widening, proarrhythmia, dizziness, visual blurring. HRS

5. Mexiletine (adjunct)
   Class: Class Ib antiarrhythmic. Dose/time: 150–200 mg three times daily. Long description: Oral lidocaine analogue sometimes used as add-on for refractory ventricular arrhythmias. Evidence is limited and individualized; GI side effects are common. Purpose: Additional VT suppression when standard options fail or are not tolerated. Mechanism: Sodium-channel blockade shortening action potential in ischemia-prone tissue; effect in ARVD/C is variable. Side effects: Nausea, tremor, neurologic effects, rare proarrhythmia. HRS

6. Standard heart-failure therapies when indicated (ACEi/ARB/ARNI, MRA)
   Class: Neurohormonal blockade (ACEi/ARB/ARNI) and aldosterone antagonists. Dose/time: Per HF guidelines (e.g., lisinopril 5–40 mg/day; valsartan/sacubitril per titration). Long description: Some ARVD/C patients develop right-sided and/or left-sided heart failure. Guideline-directed medical therapy improves symptoms and may slow remodeling though data are extrapolated from non-ARVD/C HF. Purpose: Treat ventricular dysfunction and HF symptoms. Mechanism: RAAS and sympathetic blockade reduce wall stress and adverse remodeling. Side effects: Hypotension, renal dysfunction, hyperkalemia (MRA). HRS

7. Diuretics for congestion (when heart failure present)
   Class: Loop/thiazide diuretics. Dose/time: Furosemide individualized. Long description: Used to relieve fluid overload (edema, abdominal fullness) in right-sided failure. Purpose: Symptom control. Mechanism: Increase sodium and water excretion to lower venous pressure. Side effects: Electrolyte loss, kidney effects, dizziness. HRS

8. Anticoagulation in specific scenarios
   Class: Anticoagulants (DOAC/warfarin). Dose/time: Risk-based. Long description: Thrombus can rarely form in enlarged, akinetic RV/LV segments or with atrial arrhythmias; anticoagulation may be used when thrombus or AF/flutter is documented or risk is high. Purpose: Prevent embolic events. Mechanism: Inhibit coagulation pathways to reduce clot formation. Side effects: Bleeding risk; drug interactions. HRS

9. Electrolyte repletion (Mg/K) when low
   Class: Supplements/IV repletion as needed. Dose/time: Per labs. Long description: Low potassium or magnesium increases risk of ventricular arrhythmias and torsades with certain antiarrhythmics. Purpose: Reduce proarrhythmia. Mechanism: Stabilize membrane potentials and repolarization. Side effects: GI upset with oral Mg; hyperkalemia if excessive replacement. AHA Journals

10. Sedation/anxiolytics during ICD storm (acute setting)
    Class: Short-term benzodiazepines/sedation. Dose/time: Acute use in hospital. Long description: In electrical storm, breaking the adrenergic surge helps restore rhythm stability alongside antiarrhythmics and ablation. Purpose: Reduce sympathetic drive. Mechanism: CNS anxiolysis dampens catecholamines. Side effects: Sedation, respiratory depression if misused. HRS

(I can continue to 20—e.g., ivabradine for rate control when β-blocker limited; short-term IV lidocaine; amiodarone-sparing strategies; careful use of calcium-channel blockers generally not helpful for VT; therapy for myocarditis-overlap if present; and tailored use of ARNI/MRA/SGLT2 when LV involvement advances.)

---

Dietary molecular supplements

Evidence for supplements modifying ARVD/C is weak. Use only under clinician guidance, mainly to correct a deficiency or support general heart health. I’ll be explicit where data are limited.

1. Magnesium (only if low)—May reduce ectopy risk when deficient; avoid excess. Typical oral 200–400 mg/day; mechanism: cofactor stabilizing ion channels and repolarization. Evidence supports correction of deficiency in arrhythmia care, not ARVD/C disease modification. AHA Journals

2. Potassium (if low)—Correct hypokalemia to reduce ventricular arrhythmias; dose individualized to labs; mechanism: maintains resting membrane potential. Not a disease-modifier. AHA Journals

3. Omega-3 fatty acids—Mixed arrhythmia data; no proof they reduce malignant VT in ARVD/C. If used for general cardiometabolic benefit, keep doses modest and discuss with your doctor. Mechanism: membrane effects and anti-inflammatory actions; dose often 1 g/day EPA/DHA. HRS

4. Coenzyme Q10—Evidence limited in inherited arrhythmia cardiomyopathies; may support general mitochondrial function; typical 100–200 mg/day. Not proven to prevent VT/ICD shocks in ARVD/C. HRS

5. Vitamin D (if deficient)—Correct deficiency for general health; no ARVD/C-specific arrhythmia data. Dose: per labs/guidelines. Mechanism: pleiotropic; deficiency correction may help muscle/immune health. HRS

6. Thiamine (if low)—Consider if diuretics cause losses or diet is poor; deficiency can worsen heart function, but not specific to ARVD/C. Dose: per labs. HRS

7. Sodium restriction (dietary pattern)—Helps if heart failure develops (fluid control); mechanism: reduces volume load. No direct arrhythmia effect. Aim for <2–3 g/day sodium if HF present per clinician. HRS

8. Caffeine moderation—Not a supplement, but practical: limit high-dose caffeine/energy products that can trigger palpitations. Mechanism: adenosine antagonism raises adrenergic tone. HRS

9. Alcohol moderation/avoidance—Alcohol can trigger arrhythmias in susceptible people; consider strict limits. HRS

10. Electrolyte-balanced hydration—Use balanced fluids in hot weather/exertion within allowed intensity; mechanism: maintains K/Mg levels and reduces ectopy. HRS

---

Immunity-booster / regenerative / stem-cell” drugs

There are no proven “immunity-booster” or stem-cell drugs that modify ARVD/C in clinical practice today. Use of experimental cell or gene therapies should only occur in regulated clinical trials. Below are clarifications (not recommendations to use): HRS

1. Anti-inflammatory therapy in overlap-myocarditis cases—Occasionally considered if biopsy/imaging proves active inflammation; this is not routine ARVD/C care. Dose/mechanism depend on diagnosis (e.g., myocarditis). HRS

2. Gene-targeted therapy (research stage)—Future strategies may target desmosomal pathways or mutant-protein effects, but no approved therapy exists yet for ARVD/C. HRS

3. Cell therapy (research stage)—No convincing evidence of benefit in ARVD/C; risk of arrhythmia may increase if grafts create heterogeneity. Only in trials. HRS

4. Antifibrotic strategies (experimental)—Animal/early translational studies look at fibrogenesis pathways; not available clinically for ARVD/C. HRS

5. Autonomic modulation (e.g., left cardiac sympathetic denervation) in refractory storm—Rarely considered by specialized teams for refractory VT after all standard options; evidence is limited and extrapolated from other channelopathies. HRS

6. Immunomodulators for sarcoid/amyloid phenocopies—Relevant only if diagnosis is not ARVD/C but an inflammatory/infiltrative disease mimicking it. HRS

---

Procedures / surgeries

1. Implantable cardioverter-defibrillator (ICD)
   Procedure: A pulse generator and lead(s) are implanted to detect and treat life-threatening VT/VF automatically. Why done: It is the most effective protection against sudden cardiac death in high-risk ARVD/C (e.g., prior sustained VT/VF, extensive disease with risk markers). Programming and meds aim to reduce shocks. AHA Journals+1

2. Catheter ablation (endocardial ± epicardial)
   Procedure: Electrophysiologists map scar-related circuits and cauterize them to reduce VT. Epicardial ablation is frequently needed because scar often sits on the outer RV wall. Why done: To reduce VT recurrences and ICD shocks when medications are not enough. Multiple procedures may be needed as disease progresses. AHA Journals

3. Subcutaneous ICD (S-ICD) selection
   Procedure: ICD without transvenous leads; placed under the skin with a subcutaneous lead. Why done: Considered in younger patients to avoid transvenous lead complications when pacing is not required (no ATP/pacing). Choice depends on VT profile and need for ATP. AHA Journals

4. Cardiac transplantation (advanced cases)
   Procedure: Heart transplant for end-stage biventricular failure or uncontrollable arrhythmias despite maximal therapy. Why done: Salvage therapy for severe, refractory disease with poor quality of life or high mortality risk. HRS

5. Temporary mechanical circulatory support in electrical storm (bridge)
   Procedure: Short-term devices (e.g., ECMO) in ICU as a bridge to ablation or transplant in catastrophic, refractory arrhythmias. Why done: Stabilize the patient while definitive therapy is planned. HRS

---

Preventions

1. Avoid competitive/high-intensity sports; stick to low-intensity plans cleared by your team. portailvasculaire.fr

2. Keep up with regular rhythm monitoring and follow-up CMR as your doctor advises. PMC

3. Take medicines exactly as prescribed; do not stop suddenly. AHA Journals

4. Correct low potassium/magnesium; avoid dehydration. AHA Journals

5. Avoid stimulants/energy products and recreational drugs that raise heart rate. HRS

6. Teach family CPR; consider AED access in key settings. HRS

7. Manage stress and sleep; treat sleep apnea. HRS

8. Promptly report syncope, near-syncope, or new palpitations. HRS

9. Family genetic counseling and targeted testing when a pathogenic variant is known. HRS

10. Plan pregnancy with your cardiology team to adjust meds safely. HRS

---

When to see a doctor

Go to emergency care now for fainting, nearly fainting, chest pain, sustained rapid pounding heartbeat, or any ICD shock (especially repeated shocks). Early evaluation can prevent cardiac arrest. For less severe but new symptoms (increasing palpitations, exercise intolerance, swelling, or new breathlessness), contact your cardiologist urgently for medication review and monitoring. AHA Journals+1

---

What to eat and what to avoid

Eat a heart-healthy pattern: vegetables, fruits, whole grains, lean proteins, and balanced electrolytes—especially if you’re on diuretics or sweating in hot weather. If you have fluid retention or heart failure, follow your clinician’s advice on fluids and sodium. Avoid energy drinks and stimulant supplements; limit alcohol; keep caffeine modest. These steps help limit triggers and support overall heart health, though they do not replace medical therapy. HRS

---

Frequently asked questions (FAQ)

1) Is ARVD/C the same as ACM?
ARVD/C is a form of ACM that mainly involves the right ventricle; ACM is the umbrella term that also includes left-dominant and biventricular forms. HRS

2) Can I ever exercise?
Yes, but keep intensity low to moderate under medical guidance; competitive/high-intensity exercise is discouraged because it raises arrhythmia risk and speeds disease progression. portailvasculaire.fr

3) Do medicines cure ARVD/C?
No. Medicines reduce arrhythmias and symptoms; ICDs prevent sudden death. There is no approved disease-modifying drug yet. AHA Journals+1

4) When is an ICD recommended?
After sustained VT/VF or when risk markers and clinical judgment show high risk. Decisions are individualized by your electrophysiologist. AHA Journals

5) Will catheter ablation cure VT forever?
It can greatly reduce VT and ICD shocks, but new arrhythmias may appear as disease evolves; repeat ablation can be needed. AHA Journals

6) Should my family be tested?
Yes, when a pathogenic variant is found, first-degree relatives should get counseling and consider targeted genetic testing and periodic cardiac checks. HRS

7) Are supplements helpful?
Only to correct true deficiencies (e.g., K/Mg). No supplement has proven to prevent malignant arrhythmias in ARVD/C. AHA Journals

8) Is pregnancy safe?
Often yes, with a plan made by your cardiology and obstetric teams, plus medication adjustments and monitoring. HRS

9) Can stress trigger arrhythmias?
Yes. Stress raises adrenaline and may trigger VT; stress-reduction techniques help alongside medical treatment. HRS

10) Why are sports restricted even if I feel well?
Because intense exercise accelerates disease and increases sudden-death risk even in gene-positive people without symptoms. portailvasculaire.fr+1

11) How often do I need check-ups?
At least yearly, often more often early after diagnosis or when therapy changes; remote ICD/rhythm checks may be more frequent. HRS

12) Are there new diagnostic rules?
Yes—2010 Task Force Criteria were updated by the 2020 Padua criteria, with further 2024 expert refinements for left-dominant disease. PubMed+2PMC+2

13) Is left-dominant disease real?
Yes. Many patients have left-dominant or biventricular involvement; modern criteria help doctors recognize it. PMC

14) Is ARVD/C the same as myocarditis or sarcoidosis?
No, but they can mimic each other. The HRS document places ARVD/C within a spectrum and stresses careful evaluation to rule out phenocopies like cardiac sarcoidosis. HRS

15) What research is coming?
Better risk tools, refined criteria, and possible gene-/pathway-targeted therapies are under study; none are approved yet. PubMed

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 23, 2025.